Study with 3% THC and 3% CBD
Preclinical studies showed significant reduction of Psoriasis biomarkers (IL-8 and IL-33) and reduction in keratinocytes. (p14 presentation)
During this period, we completed a pre-clinical efficacy study in psoriasis with unique,
and what we believe may be breakthrough results; we previously reported an up to 70% reduction in biological markers directly related to this disease;
BOT has a 5% CBD that functions as a 20% solution thanks to Permetrex.
Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-169
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.020(5.97%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 36.0¢ | 33.3¢ | $2.622M | 7.530M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 106888 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 462320 | 5 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
